8-K: PAVmed Inc. Issues Series C Convertible Preferred Stock in Debt Exchange and Securities Purchase Agreements

PAVmed Inc. has entered into agreements to exchange existing debt for Series C Convertible Preferred Stock and to sell additional shares of the same preferred stock, aiming to reduce debt and raise capital.

Summary

• PAVmed Inc. has agreed to exchange $22.347 million of its senior secured convertible notes for 22,347 shares of Series C Convertible Preferred Stock.
• The company will also sell 2,653 shares of Series C Preferred Stock for $2.653 million, satisfied by the cancellation of unsecured debt obligations.
• The Series C Preferred Stock has a stated value of $1,000 per share and accrues dividends at a rate of 7.875% per annum, payable quarterly.
• The preferred stock ranks senior to all other equity securities except for the Series B Preferred Stock, with which it is on parity.
• Each share of Series C Preferred Stock is convertible into common stock at an initial fixed conversion price of $1.068 per share, subject to adjustments.
• Holders have the option to convert at an alternate conversion price, which is the lower of the fixed conversion price or a variable price based on the VWAP of the common stock, but not less than $0.2136.
• The company has the right to redeem all or a portion of the Series C Preferred Stock at 132.5% of the stated value plus accrued dividends.
• A change of control triggers a right for holders to exchange their preferred stock for 132.5% of the stated value or a higher amount based on market price or transaction consideration.
• The company is subject to various covenants, including maintaining cash flow on a break-even basis and restrictions on incurring debt and transferring assets.
• The company will seek stockholder approval to increase the authorized shares of common stock from 50 million to 250 million shares by January 31, 2025.

Sentiment

Score: 6

Explanation: The document outlines a complex financial transaction that is generally positive for the company as it reduces debt and raises capital. However, the restrictions and covenants imposed on the company could limit its flexibility and growth potential. The sentiment is neutral to slightly positive.

Positives

• The debt exchange reduces the company's outstanding debt by $22.347 million.
• The securities purchase agreement provides an additional $2.653 million in capital.
• The Series C Preferred Stock has a fixed dividend rate of 7.875%, providing a predictable return for investors.
• The alternate conversion price provides downside protection for holders in the event of a decline in the common stock price.
• The company has the option to redeem the preferred stock, which could provide flexibility in managing its capital structure.
• The change of control provision provides additional protection for holders in the event of a merger or acquisition.

Negatives

• The company is subject to a financial covenant requiring it to maintain its cash flow on a break-even basis, which could limit its ability to invest in growth.
• The company is restricted from incurring additional debt, which could limit its financial flexibility.
• The company is restricted from transferring assets, which could limit its ability to restructure its business.
• The company is restricted from making cash distributions or loans to its subsidiaries without prior consent.
• The company is required to seek stockholder approval to increase the authorized shares of common stock, which may not be guaranteed.
• The company is required to set aside 50% of gross payments received from Lucid under the MSA after January 31, 2025, if certain conditions are met, which could limit its cash flow.

Risks

• The company's ability to meet the financial covenant of maintaining cash flow on a break-even basis is a risk.
• The company's ability to obtain stockholder approval for the increase in authorized shares is not guaranteed.
• The company's ability to complete a Qualified Company Optional Redemption by March 31, 2025, is a risk.
• The company's ability to comply with the various covenants and restrictions imposed by the agreements is a risk.
• The company's ability to maintain its listing on the Principal Market is a risk.
• The company's ability to generate sufficient cash flow to meet its obligations under the agreements is a risk.

Future Outlook

The company will seek stockholder approval to increase the authorized shares of common stock and to issue shares upon conversion of the Series C Preferred Stock. The company will also continue to seek to obtain the Stockholder Approval quarterly until such approval is obtained.

Industry Context

This announcement reflects a trend of companies using preferred stock and debt exchanges to manage their capital structure and raise funds. The use of a variable conversion price and a redemption option provides flexibility for both the company and the investors.

Comparison to Industry Standards

• The use of convertible preferred stock is a common financing method for companies in the biotech and medical device industries, particularly those that are pre-revenue or early-stage.
• The 7.875% dividend rate is within the typical range for preferred stock in this sector, although it can vary based on the company's risk profile and market conditions.
• The conversion price of $1.068 per share is a common structure, but the inclusion of an alternate conversion price with a floor of $0.2136 provides downside protection for investors, which is a feature often seen in riskier investments.
• The 132.5% redemption premium is also a common feature, designed to compensate investors for the risk of investing in a company that may not be able to repay its debt.
• The financial covenants, such as maintaining cash flow on a break-even basis, are typical for companies that are seeking to manage their cash burn and demonstrate financial discipline to investors.
• The requirement to obtain stockholder approval for the increase in authorized shares is a standard practice for companies listed on major exchanges.
• Compared to other similar companies, the terms of this agreement are relatively standard, with the inclusion of the alternate conversion price and the redemption premium being common features to attract investors.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from the issuance of new shares upon conversion of the preferred stock.
• Employees may be impacted by the company's ability to invest in growth due to the financial covenants.
• Creditors will be impacted by the reduction in the company's outstanding debt.
• Customers and suppliers may be impacted by the company's ability to operate and grow its business.

Next Steps

• The company will file a certificate of designations with the Secretary of State of the State of Delaware.
• The company will hold a stockholder meeting to approve the increase in authorized shares and the issuance of shares upon conversion of the Series C Preferred Stock.
• The company will continue to seek to obtain the Stockholder Approval quarterly until such approval is obtained.

Key Dates

Keywords

Series C Convertible Preferred Stock, Debt Exchange, Securities Purchase Agreement, Convertible Notes, Common Stock, Conversion Price, Redemption, Change of Control, Financial Covenants, Stockholder Approval